|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 800 North Capitol Street, NW, Suite 800 |
Address2 |
|
| City | Washington |
State | DC |
Zip Code | 20002 |
Country | USA |
3. Principal place of business (if different than line 2)
| City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 400531586-265
|
||||||||
|
6. House ID# 411660025
|
||||||||
| TYPE OF REPORT | 8. Year | 2024 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: John Green |
Date | 7/22/2024 5:35:04 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, mental health, opioid abuse, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, plasma therapy, and step therapy;
H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation;
Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization;
H.R.830, HELP Copays Act; S.127, Pharmacy Benefit Manager Transparency Act of 2023; H.R.3285, Fairness for Patient Medications Act; S.1339, Pharmacy Benefit Manager Reform Act; H.R.5378, Lower Costs, More Transparency Act; S.3430, Better Mental Health Care Lower-Cost Drugs and Health Extenders Act; S.2973, Modernizing and Ensuring PBM Accountability Act; H.R.6283, DRUG Act; H.R.2630, Safe Step Act.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Todd M. |
Weiss |
|
|
|
Mathew |
Lapinski |
|
|
|
Jason |
Van Pelt |
|
|
|
Hunter |
Moorhead |
|
|
|
Jason |
Gleason |
|
|
|
Brittany |
Hernandez |
|
|
|
Ivelisse |
Porroa-Garcia |
|
|
|
Cheryl |
Jaeger |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; Drug Pricing;
H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation;
CMMI Proposed Accelerated Approval Payment Policy;
CMMI Medicaid Proposed Rebate Rule.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Todd M. |
Weiss |
|
|
|
Mathew |
Lapinski |
|
|
|
Jason |
Van Pelt |
|
|
|
Hunter |
Moorhead |
|
|
|
Jason |
Gleason |
|
|
|
Brittany |
Hernandez |
|
|
|
Ivelisse |
Porroa-Garcia |
|
|
|
Cheryl |
Jaeger |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
Issues related to federal health programs and prescription drugs; FY2025 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations; FY2025 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Todd M. |
Weiss |
|
|
|
Mathew |
Lapinski |
|
|
|
Jason |
Van Pelt |
|
|
|
Hunter |
Moorhead |
|
|
|
Jason |
Gleason |
|
|
|
Brittany |
Hernandez |
|
|
|
Ivelisse |
Porroa-Garcia |
|
|
|
Cheryl |
Jaeger |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
Issues related to tax reform.
Tax issues related to H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation.
Issues related to R&D tax credit; H.R.7024, Tax Relief for American Families and Workers Act of 2024.
Issues related to orphan drug tax credit; H.R.5539/S.3131, ORPHAN Cures Act.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Todd M. |
Weiss |
|
|
|
Mathew |
Lapinski |
|
|
|
Jason |
Van Pelt |
|
|
|
Hunter |
Moorhead |
|
|
|
Jason |
Gleason |
|
|
|
Brittany |
Hernandez |
|
|
|
Ivelisse |
Porroa-Garcia |
|
|
|
Cheryl |
Jaeger |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
Biopharmaceutical innovation and patent policy issues.
Bayh-Dole march-in rights policy issues.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Todd M. |
Weiss |
|
|
|
Mathew |
Lapinski |
|
|
|
Jason |
Van Pelt |
|
|
|
Hunter |
Moorhead |
|
|
|
Jason |
Gleason |
|
|
|
Brittany |
Hernandez |
|
|
|
Ivelisse |
Porroa-Garcia |
|
|
|
Cheryl |
Jaeger |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRD
16. Specific lobbying issues
Issues related to pharmaceutical IP and supply chain.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Todd M. |
Weiss |
|
|
|
Mathew |
Lapinski |
|
|
|
Jason |
Van Pelt |
|
|
|
Hunter |
Moorhead |
|
|
|
Jason |
Gleason |
|
|
|
Brittany |
Hernandez |
|
|
|
Ivelisse |
Porroa-Garcia |
|
|
|
Cheryl |
Jaeger |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address |
|
||||||
| City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
| City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
3 |
|
||||||
| 2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
| Lobbyist Name | Description of Offense(s) |